ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 733

Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Kuninobu Wakabayashi, Nao Oguro, Yoko Miura, Sho Ishii, Shinya Seki, Masayu Umemura, Takahiro Tokunaga, Hiroyuki Tsukamoto, Sakiko Isojima, Hidekazu Furuya, Ryo Yanai, Kumiko Otsuka, Ryo Takahashi, Takeo Isozaki, Nobuyuki Yajima, Yusuke Miwa and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ANCA, nephritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: It is important to determine the biomarkers for assessing disease activity of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Plasma levels of fibrin/fibrinogen degradation products (FDP) are fibrinolytic markers and elevates after any thrombotic event. We hypothesized that plasma levels of FDP reflect to hypercoagulable state and thrombosis in AAV. The purpose of the present study is to investigate whether plasma levels of FDP could be an indicator of disease states and complications of organ involvements in patients of AAV.

Methods: Patients with microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) who were admitted to Showa University Hospital for induction therapy and had their plasma FDP levels checked in the active state from October 2005 to May 2013 were retrospectively included. Plasma FDP levels were compared between the active and inactive states of AAV. Among patients in the active state, vasculitis disease clinical activity was assessed using Birmingham Vasculitis Activity Scores (BVAS), and the relationship between plasma FDP levels and BVAS, scores of each system were discussed. Plasma FDP levels were evaluated for differences in each disease and were compared between patients with and without complications of nephritis, interstitial pneumonia and peripheral neuropathy. Laboratory markers of AAV and nephritis activity were examined to determine their correlations with plasma FDP levels.

Results: Thirty-seven MPA, 12 GPA, and 6 EGPA patients were included. Plasma FDP levels were high in the active state and decreased significantly after therapy (p<0.001). Among patients in the active state, plasma FDP levels significantly correlated with BVAS (rs=0.35, p<0.05). Especially, positive correlations were observed among plasma FDP levels and the system of general (rs=0.57, p<0.001) and renal involvement (rs=0.33, p<0.05) in the systems of BVAS. Plasma FDP levels were significantly higher in patients with MPA than in patients with GPA (p<0.05) and with EGPA (p<0.05). Although plasma FDP levels were significantly higher in patients with nephritis than in patients without nephritis (p<0.01), there were no differences between patients with and without complications of interstitial pneumonia and peripheral neuropathy. Plasma FDP levels significantly correlated with serum C-reactive protein levels (rs=0.52, p<0.001), peripheral blood neutrophil count (rs=0.53, p<0.001), plasma D-dimer levels (rs=0.87, p<0.001), serum creatinine levels (rs=0.34, p<0.05), estimated glomerular filtration rates (rs=-0.43, p<0.01), and urinary N-acetyl-beta-D-glucosaminidase index (rs=0.37, p<0.05). Plasma FDP levels were significantly higher in the patients with proteinuria (p<0.01) and hematuria (p<0.05).

Conclusion: Plasma FDP levels might be a useful indicator of disease activity and complications of nephritis in patients with AAV. Better understanding of the association of thrombosis with inflammation in AAV might lead to development new approaches to therapy.


Disclosure:

K. Wakabayashi,
None;

N. Oguro,
None;

Y. Miura,
None;

S. Ishii,
None;

S. Seki,
None;

M. Umemura,
None;

T. Tokunaga,
None;

H. Tsukamoto,
None;

S. Isojima,
None;

H. Furuya,
None;

R. Yanai,
None;

K. Otsuka,
None;

R. Takahashi,
None;

T. Isozaki,
None;

N. Yajima,
None;

Y. Miwa,
None;

T. Kasama,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-levels-of-fibrinfibrinogen-degradation-products-might-be-a-useful-indicator-of-disease-activity-classification-and-nephritis-complications-in-antineutrophil-cytoplasmic-antibody-associated-va/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology